Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04659616|
Recruitment Status : Recruiting
First Posted : December 9, 2020
Last Update Posted : July 12, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia||Drug: Cytarabine Drug: Daunorubicin Drug: Pemigatinib||Phase 1|
I. To determine the maximum tolerated dose of pemigatinib (INC054828) following standard of care induction chemotherapy.
I. To assess preliminary efficacy associated with study intervention. II. To assess the safety profile of the study intervention. III. To evaluate time-to- marrow recovery between cycles of pemigatinib.
I. Assess minimal residual disease (MRD) by fluorescent in situ hybridization (FISH), reverse transcriptase-polymerase chain reaction (RT-PCR), and/or next-generation sequencing of acute myeloid leukemia (AML) genetic abnormalities in bone marrow and blood.
II. Quantify FGF2/FGFR immunohistochemical staining of marrow core biopsies and compare to historical controls at various timepoints.
III. Assess ex vivo sensitivity of patient-derived mononuclear cells to pemigatinib with and without FGF2 supplementation.
IV. Evaluate pemigatinib-induced changes in stromal expression using cultured bone marrow samples and compare to historical controls.
V. Evaluate the impact of pemigatinib on the need for intravenous (IV) phosphate replacement after chemotherapy.
OUTLINE: This is a dose-escalation study of pemigatinib followed by a dose-expansion study.
INDUCTION: Patients receive cytarabine IV on days 1-7, daunorubicin IV on days 1-3, and pemigatinib orally (PO) once daily (QD) on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients with hematologic count recovery (assessed between days 25-42) after induction proceed to consolidation therapy.
CONSOLIDATION: Patients receive high dose cytarabine IV twice daily (BID) on days 1, 3, and 5, and pemigatinib PO QD on days 8-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression of unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 24 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Phase 1, Open-Label Study of the FGFR Inhibitor Pemigatinib (INCB054828) Administered After Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With Adverse or Intermediate Risk Cytogenetics|
|Actual Study Start Date :||January 14, 2021|
|Estimated Primary Completion Date :||February 1, 2024|
|Estimated Study Completion Date :||August 1, 2024|
Experimental: Treatment (cytarabine, daunorubicin, pemigatinib)
INDUCTION: Patients receive cytarabine IV on days 1-7, daunorubicin IV on days 1-3, and pemigatinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients with hematologic count recovery (assessed between days 25-42) after induction proceed to consolidation therapy.
CONSOLIDATION: Patients receive high dose cytarabine IV BID on days 1, 3, and 5, and pemigatinib PO QD on days 8-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression of unacceptable toxicity.
- Incidence of dose limiting toxicities (DLTs) [ Time Frame: From cycle 1 day 8, until 14 days after cycle 1 day 28 (up to 42 days) ]Will be summarized using the proportion and exact binomial confidence interval. DLTs will be summarized at each dose level by severity and major organ site according to the Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.
- Rate of composite complete remission (cCR) [ Time Frame: From cycle 1 day 1, until blood cell count recovery after induction (day 25-42) ]
- Duration of remission (DOR) [ Time Frame: Date of first response (>= immune complete remission) till date of documented relapse assessed up to 2 years from last dose of study intervention ]
- Event-free survival (EFS) [ Time Frame: From cycle 1 day 1, until date of primary refractory disease, progression, relapse, or death from any cause, assessed up to 2 years from last dose of study intervention ]
- Relapse-free survival (RFS) [ Time Frame: Date of first response (>= complete remission with incomplete blood count recovery [CRi]), until date of relapse or death from any cause, assessed up to 2 years from last dose of study intervention ]
- Overall survival (OS) [ Time Frame: From cycle 1 day 1, until date of death from any cause, assessed up to 2 years from last dose of study intervention ]Estimated with the Kaplan-Meier method.
- Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: From cycle 1 day 8, until 90 days after last dose of study intervention ]Will be determined for the safety analysis set (i.e., study participants who receive at least one dose of pemigatinib) and the subset of safety evaluable patients treated at the MTD. The point estimate and 95% confidence interval will be reported. Each toxicity event will be tabulated and summarized by severity and major organ site according to the CTCAE v5.0. Will be evaluated in the dose determining and dose expansion cohorts separately as well as combined.
- Incidence of non-treatment related adverse events (AEs) [ Time Frame: From cycle 1 day 8, until 90 days after last dose of study intervention ]Will be determined for the safety analysis set (i.e., study participants who receive at least one dose of pemigatinib) and the subset of safety evaluable patients treated at the MTD. The point estimate and 95% confidence interval will be reported. Each toxicity event will be tabulated and summarized by severity and major organ site according to the CTCAE v5.0. Will be evaluated in the dose determining and dose expansion cohorts separately as well as combined
- Time-to-marrow recovery [ Time Frame: Baseline (cycle 1 day 1), until time of count recovery ]Defined as absolute neutrophil count (ANC) >= 1 x 10^9 /L and platelets >= 100 x 10^9/L.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- PRE-SCREENING INCLUSION CRITERIA:
- Ability to understand and the willingness to sign a written informed consent document
- Age >= 18 years at time of informed consent. Both men and women of all races and ethnic groups will be included
- Participants must consent to a bone marrow aspirate/biopsy that will be collected prior to start of planned 7+3 induction therapy. Patients with known favorable risk AML (ELN Guidelines) or FLT3 mutations should not be pre-screened. If the risk category is unknown, then it is okay to pre-screen patients for study. Adverse or intermediate risk needs to be confirmed prior to treatment with pemigatinib (during screening period) as outlined below
- TREATMENT INCLUSION CRITERIA:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
For dose-determining portion of study, study population is limited to: Newly diagnosed, morphologically documented AML, based on the World Health Organization (WHO) 2008 classification, with cytogenetics or mutations associated with the adverse prognostic risk group per European Leukemia Net (ELN) guidelines. These include:
- t(6;9)(p23;q34.1); DEK-NUP214
- t(v;11q23.3); KMT2A rearranged
- t(9;22)(q34.1;q11.2); BCR-ABL1
- inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)
- -5 or del(5q); -7; -17/abn(17p)
- Complex karyotype - defined as three or more unrelated chromosome abnormalities in the absence of 1 of the WHO-designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1
- Monosomal karyotype - defined by the presence of 1 single monosomy (excluding loss of X or Y) in association with at least 1 additional monosomy or structural chromosome abnormality (excluding core-binding factor AML)
- Mutated RUNX1
- Mutated ASXL1
- Mutated TP53
For the dose-expansion portion of the study, study population is limited to: Newly diagnosed, morphologically documented AML, based on the World Health Organization (WHO) 2008 classification, with a cytogenetic or mutation profile encompassing the intermediate prognostic risk groups per European Leukemia Net (ELN) guidelines.2 These include:
- Wild-type or NPM1
- t(9;11)(p21.3;q23.3); MLLT3-KMT2A
- Cytogenetic abnormalities not classified as favorable or adverse
- Serum creatinine clearance >= 30 mL/min (as calculated by Cockcroft-Gault formula) (on or by day 8 of induction therapy, prior to starting pemigatinib)
- Serum phosphate within institutional upper limit of normal (ULN) or can be corrected with supplementation/ phosphate binders to be within institutional ULN (on or by day 8 of induction therapy, prior to starting pemigatinib)
- Serum electrolytes within institutional ULN: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected (on or by day 8 of induction therapy, prior to starting pemigatinib)
- Total serum bilirubin =< 3 x ULN (on or by day 8 of induction therapy, prior to starting pemigatinib)
- Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 3 x ULN (on or by day 8 of induction therapy, prior to starting pemigatinib)
- Participants must consent to standard of care bone marrow aspirate/biopsies during treatment. Bone marrow biopsies will be obtained prior to study, on day 21 (+/-3 days, if considered institutional standard of care), after recovery from induction therapy, and at the end of consolidation and/or prior to allogeneic stem cell transplant
- Female participants of childbearing potential must agree to use effective contraception (2 forms of contraception or abstinence) from the screening visit until 6 months following the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- Male patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from the screening visit until 3 months following the last dose of study treatment. The male participant must also refrain from sperm donation from the screening visit until 3 months following the last dose of study treatment
- PRE-SCREENING EXCLUSION CRITERIA:
- Diagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype) per WHO classification
- AML with FLT3 mutations that qualify for standard of care treatment with 7+3 and midostaurin (e.g. FLT3 ITD or TKD with allelic ratio >0.05)
- Favorable risk AML: inv(16), t(8;21) or NPM1 mutations without FLT3 ITD mutations
- Any cancer-directed therapy within 2 weeks prior to starting planned 7+3 induction regimen, with the exception of hydroxyurea, which is allowed to control white blood cell count, or empiric all-trans retinoic acid (ATRA) for suspected APL
- Prior receipt of a selective FGFR inhibitor
- Known liver disease
History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues
- Except for commonly observed calcifications in soft tissues such as the skin, kidney tendon, or vessels due to injury, disease, or aging in the absence of systemic mineral imbalance)
- History of hypovitaminosis D being actively treated with supraphysiologic doses (e.g., 50,000 IU/weekly) to replenish the deficiency. Supraphysiologic doses of vitamin D need to be discontinued prior to starting pemigatinib. Vitamin D supplements are allowed
Untreated human immunodeficiency virus (HIV) or active hepatitis C detectable by PCR, or chronic hepatitis B
- Individuals positive for hepatitis B core antibody who are receiving intravenous immunoglobulin (IVIg) are eligible if HepB PCR is negative
- History of cerebrovascular accident or intracranial hemorrhage within 2 months of enrollment
- Unwillingness to receive infusion of blood products
- Inability to take oral medication
- Gastrointestinal condition/disorders that may raise gastric and/or small intestinal pH that could interfere with absorption, metabolism, or excretion of pemigatinib
- Known history and/or current evidence of ectopic mineralization/calcification, including (but not limited to): soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification
- Concurrent active malignancy with expected survival of < 1 year
- Active central nervous system involvement with AML
- TREATMENT EXCLUSION CRITERIA:
- Clinically significant coagulation abnormality (e.g., disseminated intravascular coagulation) that is present on or by day 8 of induction therapy prior to starting pemigatinib
Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from day 1 of planned induction therapy, New York Heart Association class III or IV congestive heart failure, and uncontrolled arrhythmia (participants with pacemaker or with atrial fibrillation and well controlled heart rate are allowed). History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
- A screening QT interval by Fridericia's Correction Formula (QTcF) interval > 480 ms will result in exclusion.
- For participants with an intraventricular conduction delay (QRS interval > 120 ms), the JTc interval may be used in place of the QTc with approval from Sponsor-Investigator. The JTc must be =< 340 ms if JTc is used in place of the QTc.
- Left ventricular ejection fraction (LVEF) by echocardiogram < 45% prior to initiating pemigatinib
- Active infection that is not well-controlled by antibacterial or antiviral therapy
Current use of prohibited medications including use of any potent CYP3A4 inducers within 14 days or five half-lives (whichever is longer) before the first dose of study drug.
- Use of CYP3A4 inhibitors should be avoided but, if medically necessary, is permitted with a dose reduction of study drug
- Use of moderate CYP3A4 inhibitors are permitted.
- Based on the low overall bioavailability of topical ketoconazole, there are no restrictions on topical ketoconazole
- Current use of prohibited medication
- Hypersensitivity to pemigatinib, or its excipients, when administered alone
- Current evidence of corneal disorder/keratopathy, including (but not limited to): bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjuctivitis, etc., as confirmed by ophthalmologic examination
- Pregnancy or breastfeeding at the time of enrollment
- Any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the protocol
- Active central nervous system involvement with AML
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04659616
|United States, Oregon|
|OHSU Knight Cancer Institute||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: Elie Traer 503-494-3553 firstname.lastname@example.org|
|Principal Investigator: Elie Traer|
|Principal Investigator:||Elie Traer||OHSU Knight Cancer Institute|
|Responsible Party:||Elie Traer, MD PhD, Principal Investigator, OHSU Knight Cancer Institute|
|Other Study ID Numbers:||
NCI-2020-05267 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
STUDY00020009 ( Other Identifier: OHSU Knight Cancer Institute )
|First Posted:||December 9, 2020 Key Record Dates|
|Last Update Posted:||July 12, 2022|
|Last Verified:||July 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Topoisomerase II Inhibitors